Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.
CanSino Biologics Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual financial results of the company and its subsidiaries for the year ended December 31, 2025. The board will also consider the publication of these results and evaluate whether to recommend a final dividend, a decision that could affect shareholder returns and signal management’s view of the company’s financial strength and future prospects.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The company focuses on the research, development and commercialization of vaccines and other biologic products, serving healthcare markets that demand innovative preventive and therapeutic solutions.
Average Trading Volume: 933,726
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.69B
For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.